[PDF] Top 20 DPP-4 inhibitors in the treatment of type 2 diabetes.

... DPP-4 inhibitors are generally well-tolerated, and no increase in adverse events was noted compared to placebo or other comparatives, but again slight differences may exist between the ... Voir le document complet

... instead of < 7% (53 mmol/mol). 3.2.4. Gliptins combined with insulin in type 2 diabetes mellitus Insulin therapy in T2DM patients is frequently initiated while oral ... Voir le document complet

... therapies in this respect [65]. Thiazide diuretics, including thiazide-type (chlorothiazide and hydrochlorothiazide) and thiazide-like diuretics (indapamide and chlorthalidone), have been used for ... Voir le document complet

... administration of other glucose lowering agents or cardiovascular agents commonly used in patients with type 2 ...influence the pharmacokinetic parameters of dapagliflozin, ... Voir le document complet

... arrival of the SGLT2 inhibitors may be viewed as an exciting opportunity to review our concept of how best to treat type 2 ...because of their specific and ... Voir le document complet

... Introduction Type 2 diabetes (T2D) is a chronic progressive metabolic disease characterized by hyperglycaemia, due to insulin resistance/insufficient insulin production [ 1 ...risk of ... Voir le document complet

... from the ADVANCE 2 and VADT 3 studies reported no increase in mortality in intensively treated ...Meta-analyses of the three trials, and of the UKPDS and the ... Voir le document complet

... : DPP-4 inhibitor ; GLP-1 receptor agonist ; Incretin ; Sitagliptin ; Exenatide ; Liraglutide ...Introduction Type 2 diabetes mellitus (T2DM) is a complex disease that involves a ... Voir le document complet

... The results suggest that 11 patients with IGT would need to be treated for ...event of development of ...risk of developing T2DM irrespective of age, sex, and BMI. If the ... Voir le document complet

... ‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice? Despite being a common feature in clinical practice and a major challenge for healthcare providers involved ... Voir le document complet

... ACE inhibitors, or angiotensin II receptor blockers truly prevent diabetes or delay its onset cannot be determined completely by the existing ...delaying the onset of diabetes is ... Voir le document complet

... amplitude of hyperglycemia. [80, 81] In a meta-analysis of RCTs, no signal of increased risk for DKA was observed for SGLT2is as a class (MH-OR, ...when the drug is properly prescribed, ... Voir le document complet

... improvement of postprandial hyperglycaemia, thereby reducing the stress on overworked β cells ...changes in these Japanese patients, 4 in view of the fact that drug ... Voir le document complet

... observed in RCTs have also been confirmed by real-life data from various studies performed in the US [72], Italy [73] and Japan ...However, the results can vary according to the ... Voir le document complet

... metformin treatment at baseline and OA outcome during follow up (adjusted HR = ...However, in a case-control study performed in Taiwan, patients who have OA and T2DM receiving combination NSAIDs and ... Voir le document complet

... tolerance in people with and without diabetes. 4 However, at the end of Chiasson and colleagues' trial, and by contrast with DPP, all patients were given single-blind placebo for ... Voir le document complet

... for the DURATION-1 Study ...for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority ...1240-50. 4 Bergenstal R, Wysham C, Ping Y, Macconell ... Voir le document complet

... Following the withdrawal of (dex)fenfluramine, rimonabant and sibutramine, orlistat, which acts via a peripheral rather than central mechanism, remains the only approved anti- obesity drug for ... Voir le document complet

... a DPP-4 inhibitor to manage hyperglycaemia in T2DM, each pharmacological class presenting some advantages and ...disadvantages. The clinical results of the large, long-term, ... Voir le document complet

... Currently, in most countries, the clinician has the choice between sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins), [5] ... Voir le document complet